Co-authored by Paulo Thiessen
“Let my inspiration flow, in token rhyme suggesting rhythm.” —Grateful Dead
Brazil entered 2026 not with a celebration, but with a reckoning. In the final week of January, the country approved a new regulatory framework for medicinal cannabis, and in doing so crossed a line it had spent decades carefully circling. This was not a sudden conversion, nor a sweeping political victory. It was something more complicated and far more honest. Brazil acknowledged, at last, that cannabis belongs within the health system, and that keeping it outside that system had never been a technical necessity. It was a political decision. One that reality had already rendered obsolete.
For patients, families, doctors, and caregivers across Brazil, treatment never waited for permission. It never paused for parliamentary debate or regulatory drafts. Cannabis medicine existed in practice long before it existed comfortably in law. Court injunctions, patient associations, improvised import schemes, and fragile legal exceptions became the scaffolding of care. The State arrived late to a conversation that had been ongoing in kitchens, clinics, and courtrooms for years. Still, when the State does arrive, it matters. Regulation may trail reality, but once it appears, it reshapes everything around it.
For the first time, Brazil’s National Health Surveillance Agency, ANVISA, formally authorizes cannabis cultivation on Brazilian soil by approved legal entities, under defined purposes and strict sanitary oversight. This single shift moves the country away from a system built almost entirely on exceptions and toward one grounded in administrative rules. Brazil did not legalize cannabis. It did not open a market. What it did was arguably more consequential. It chose to begin building a domestic regulatory foundation for cannabis inside the public health system.
This foundation is cautious by design. Brazil did not swing open the door. It tested the …
Read More
Author: Bob Hoban / High Times
